Investigation launched into certain nitisinone capsules from Sweden
OTTAWA, Sept. 21, 2018 /CNW/ - The Canada Border Services Agency (CBSA) announced today that it is launching an investigation into whether or not certain nitisinone capsules originating in or exported from Sweden are being sold at unfair prices in Canada.
The investigation is the result of a complaint filed by Laboratoires KABS Inc. and its affiliate MendeliKABS Inc. which are both located in Saint-Hubert, Quebec. The complainant (comprised of both companies) alleges that the Canadian industry is facing declines in production, lost sales, reduced profitability, negative returns on investments, underutilization of production capacity and negative effects on growth. The initiation of this investigation does not prevent these goods from being imported into Canada and being made available to users.
Currently, there are 101 special import measures in force, covering a wide variety of products, from steel to refined sugar. These measures have directly helped to protect the Canadian economy and jobs in Canada.
Quick Facts
The subject goods are nitisinone capsules supplied in certain dosages. Nitisinone capsules are orally administered drugs used in the treatment of hereditary tyrosinemia type 1 (HT?1). For more product information, please refer to the CBSA's website.
This is the beginning of an investigation process in which the CBSA and the Canadian International Trade Tribunal (CITT) both play a role. The CITT will begin a preliminary inquiry to determine whether the evidence discloses a reasonable indication that imports are harming Canadian producers and will issue a decision by November 20, 2018.
Concurrently, the CBSA will investigate whether the imports are being sold in Canada at unfair prices, and will make a preliminary decision by December 20, 2018. Should the CBSA's preliminary findings indicate that exports from Sweden are being sold at unfair prices, the investigation will be continued for the purposes of making a final decision by March 20, 2019.
A copy of the Statement of Reasons, which provides more details about the investigation, will be available on the CBSA's website at www.cbsa.gc.ca/sima-lmsi within 15 days.
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.
During an illustrious 30-year...
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...